Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Granisetron clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our Turkey and Egypt registers that name Granisetron as an intervention. Synced 22 Nov 2026
2Current trials
1Recruiting now
2Lead sponsors
2Country registers
At a glance

Granisetron is named as an intervention in 2 current clinical trials in our Turkey and Egypt registers. 1 is recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Kayseri City Hospital (1). The most-studied condition is Hypotension.

Where Granisetron is approved

All regulators →

Of the three regulators tracked here, the first to approve Granisetron was the US, on 29 Dec 1993. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)
29 Dec 1993
Kytril
NDA020239 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
20 Apr 2012
Sancuso
EMA product page
First centralised authorisation
CACanada (Health Canada)
14 Jul 1994
Kytril
Notice of Compliance 5711
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Granisetron

All medicines →
ENNHS England
£182k
912 items dispensed, Sep 2025 to Aug 2026
-11% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
$3.6m
48,823 prescriptions in 2025 · Sancuso, Granisetron Hydrochloride, Sustol
+31% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Granisetron works

All drug targets →
  • Serotonin 3a (5-HT3a) receptor antagonist Antagonist
    Target: HTR3A 5-hydroxytryptamine receptor 3A
    ✓ In ChEMBL and the Guide to Pharmacology
Diseases it has been tested for in clinical trials, by furthest phase
  • Acute kidney injuryPhase 3
  • Cesarean sectionPhase 3
  • Post operative nausea and vomitingPhase 3
  • PruritusPhase 2
  • SepsisPhase 2
  • Septic shockPhase 2
  • PainPhase 1

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL289469, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2300, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Granisetron

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • IE
    Ireland: 5 products on the HPRA list
    Each product record links to the HPRA, which publishes the leaflet and SmPC.
  • EU
    European Union: Sancuso
    EMA product information: package leaflet and summary of product characteristics in every EU language.
  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Granisetron

ATC code
A04AA02
ChEMBL
CHEMBL289469
DrugBank
DB00889
PubChem CID
3510
CAS number
109889-09-0
FDA UNII
WZG3J2MCOL
Wikidata
Q596708
Wikipedia
Granisetron

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting150%
  • Active, closed150%

Trials by phase

  • Observational150%
  • Phase 4150%
01

Clinical trials of Granisetron

2 trials
StudyPhaseStatusLead sponsorRegisters
Granisetron Use, Blood Pressure, and Nausea and Vomiting During Cesarean Delivery Under Spinal Anesthesia
NCT07861737 · ClinicalTrials.gov ↗ · Hypotension, Nausea, Vomiting
Observational Recruiting Kayseri City Hospital Turkey
Occlusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders
NCT07401745 · ClinicalTrials.gov ↗ · TMD, TMD/Orofacial Pain, Temporomandibular Disorder (TMD)
Phase 4 Active, closed Mansoura University Egypt

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Granisetron across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

5 single-substance products containing Granisetron on the HPRA medicines list.

All 5 Irish products →

Supply shortages

  • Granisetron Kabi 1 mg/ml Konzentrat zur Herstellung einer Injektionslösung/InfusionslösungGermany (BfArM) · Other reason · 30 Oct 2026 to 14 Dec 2026
03

Conditions studied with Granisetron

7 conditions
Hypotension1Nausea1Vomiting1Cesarean Section1TMD1TMD/Orofacial Pain1Temporomandibular Disorder (TMD)1
04

Sponsors

lead sponsor per trial
Lead sponsorTrials
Kayseri City Hospital1
Mansoura University1
05

By country register

RegisterTrialsRecruiting
Clinical trials in Turkey11
Clinical trials in Egypt10

A trial with sites in more than one country appears in each of those registers.

06

Related compounds

07

Questions about Granisetron trials

How many clinical trials are testing Granisetron?

2 current trials in our Turkey and Egypt registers name Granisetron as a drug or biological intervention, as of the registry sync on 22 November 2026. Completed and withdrawn studies are not counted.

Are Granisetron trials recruiting patients?

Yes. 1 of the 2 trials is recruiting: 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Granisetron clinical trials?

Kayseri City Hospital (1) and Mansoura University (1). The number in brackets is how many trials each organisation leads.

Is Granisetron licensed in Ireland?

Yes. The HPRA medicines list includes 5 single-substance products containing Granisetron, for example Kytril 1 mg/1 ml solution for injection (Atnahs Pharma Netherlands B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Granisetron shortage?

The registers we track list 1 entry for Granisetron: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Granisetron works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Granisetron works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Granisetron (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.